Cidara Therapeutics, Inc. ($CDTX)
Filing Information
| Accession Number | 0001231919-26-000031 |
|---|---|
| Form Type | 4 |
| Filing Date | Jan 9, 2026 |
| Document Date | Jan 7, 2026 |
| Document | View SEC Filing |
Transactions
6
Total Shares
7,343,116
Total Value
$2,425,254,352.18
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Director | Common Stock | โ | Jan 7, 2026 | Exercise/Conversion | 1,286,786 | $0.00 | $128.68 | 4,652,309 | Indirect | See footnotes | View Details | |
Director | Common Stock | โ | Jan 7, 2026 | Sale to Issuer | 4,652,309 | $221.50 | $1,030,486,443.50 | 0 | Indirect | See footnotes | View Details | |
Director | Stock Option (right to buy) | Derivative | Jan 7, 2026 | Sale to Issuer | 22,200 | โ | โ | 0 | Indirect | See footnotes | View Details | |
Director | Stock Option (right to buy) | Derivative | Jan 7, 2026 | Sale to Issuer | 5,079 | โ | โ | 0 | Indirect | See Footnotes | View Details | |
Director | Pre-Funded Warrants (Right to Buy) | Derivative | Jan 7, 2026 | Exercise/Conversion | 1,286,786 | โ | โ | 0 | Indirect | See footnotes | View Details | |
Director | Series A Preferred Stock | Derivative | Jan 7, 2026 | Sale to Issuer | 89,956 | $15,505.00 | $1,394,767,780.00 | 0 | Indirect | See footnotes | View Details |